To the Editor:
We read with interest the article by Schnabel and colleagues 1 exploring the prognostic value of asymmetric dimethylarginine (ADMA) with regard to cardiovascular risk. Baseline serum ADMA levels in patients with coronary artery disease were associated with the primary end point of death from cardiovascular cause or nonfatal myocardial infarction, whereas no relationship was observed with death from other causes. Thus ADMA was identified as an independent risk factor beyond traditional risk factors and novel biomarkers.
Because of its role as an endogenous inhibitor of the endothelial nitric oxide synthase (eNOS), increased ADMA levels likely contribute to the development of endothelial dysfunction and coronary artery disease. 2 eNOS is also critically involved in the regulation of endothelial progenitor cells (EPC) and repair of vascular lesions. 3 Interestingly, Schmidt-Lucke et al identified an association between reduced levels of circulating EPC and incidence of subsequent cardiovascular events. 4 By multivariate analysis, reduced EPC levels were a significant independent predictor of poor prognosis, even after adjustment for traditional cardiovascular risk factors. Unfortunately, neither Schmidt-Lucke et al 4 measured ADMA levels in the investigated study cohort, nor did Schnabel et al 1 determine circulating EPC. However, the study of Schnabel et al implicates that ADMA may impair endogenous regeneration of diseased blood vessels resulting in progressive development of vascular lesions. Recently, we have shown an inverse correlation between ADMA plasma concentration and circulating EPC levels in patients with coronary artery disease. 5 Adjusting for all patient characteristics, these findings were confirmed in multivariate regression analyses. In vitro studies demonstrated the role of ADMA as an endogenous inhibitor of mobilization, differentiation, and function of EPC. Our results therefore bridge the gap between the 2 studies of Schnabel et al 1 and Schmidt-Lucke et al. 4 Increased cardiovascular risk in patients with high ADMA levels may be explained by low numbers and impaired function of EPC. Identification and development of drugs that effectively reduce ADMA levels would probably lead to a powerful treatment of coronary artery disease by preventing the direct deleterious effects of ADMA to the endothelium and increas-ing the amount and functional activity of EPC, thus strengthening the self-renewal capacity of endothelium. Such drug candidates may be certain 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, which can effectively lower ADMA plasma levels 6 and in parallel increase circulating EPC numbers. Further in-depth basic and clinical studies are clearly needed.
